{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:32:12Z","timestamp":1777728732449,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of two different doses of celecoxib and diclofenac in the treatment of Norwegian patients with ankylosing spondylitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this 12-week, double-blind, non-inferiority trial patients were randomized to 200\u2009mg once daily (qd) celecoxib, 400\u2009mg qd celecoxib, or 50\u2009mg three times daily (tid) diclofenac. The primary objective compared patients\u2019 assessments of Global Pain Intensity, measured on a visual analogue scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 330 patients were randomized (200\u2009mg celecoxib, n\u2009=\u2009107; 400\u2009mg celecoxib, n\u2009=\u2009108; diclofenac, n\u2009=\u2009115). Least squares mean changes in Global Pain Intensity at 12 weeks were \u221225.8\u2009mm, \u221230.6\u2009mm and \u221228.2\u2009mm, respectively. Both celecoxib treatment groups were non-inferior to diclofenac. More patients in the 400\u2009mg celecoxib group met the Assessments in Ankylosing Spondylitis 20 responder criteria at Week 12 (60.2%) than in the celecoxib 200\u2009mg (51.4%) and the diclofenac 50\u2009mg (57.4%) groups. Adverse events were mild-to-moderate in severity, with dyspepsia and diarrhoea the most commonly reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Celecoxib and diclofenac both provided pain reduction, in addition to improvements in disease activity and functional capacity, in patients with ankylosing spondylitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0300060516628704","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T22:28:57Z","timestamp":1458080937000},"page":"483-495","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients"],"prefix":"10.1177","volume":"44","author":[{"given":"Chris","family":"Walker","sequence":"first","affiliation":[{"name":"Pfizer Ltd, Walton-on-the-Hill, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret N","family":"Essex","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunming","family":"Li","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W","family":"Park","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"key":"bibr1-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38954.689583.DE"},{"key":"bibr2-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-002-0237-4"},{"key":"bibr3-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"bibr4-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041137"},{"key":"bibr5-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802714382"},{"key":"bibr6-0300060516628704","unstructured":"FDA Approves New Use for Pfizer\u2019s Celebrex. http:\/\/www.drugs.com\/news\/fda-approves-new-pfizer-s-celebrex-1497.html (2005, accessed 25 November 2014)."},{"key":"bibr7-0300060516628704","unstructured":"Europe approves new use for Pfizer\u2019s Celebrex drug. http:\/\/www.reuters.com\/article\/2007\/02\/23\/pfizer-celebrex-idUSL237742220070223 (2007, accessed 25 November 2014)."},{"key":"bibr8-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075309"},{"key":"bibr9-0300060516628704","first-page":"1805","volume":"33","author":"Barkhuizen A","year":"2006","journal-title":"J Rheumatol"},{"key":"bibr10-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K"},{"key":"bibr11-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1002\/art.21054"},{"key":"bibr12-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201370"},{"key":"bibr13-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201252"},{"key":"bibr14-0300060516628704","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.\n                      JAMA\n                      2000; 284: 3043\u20133045.","DOI":"10.1001\/jama.284.23.3043"},{"key":"bibr15-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"bibr16-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)02332-6"},{"key":"bibr17-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep393"},{"key":"bibr18-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1080\/030097401750065265"},{"key":"bibr19-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903018279"},{"key":"bibr20-0300060516628704","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2014.08.002"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060516628704","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0300060516628704","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300060516628704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:52:58Z","timestamp":1777459978000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0300060516628704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1177\/0300060516628704"],"URL":"https:\/\/doi.org\/10.1177\/0300060516628704","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]}}}